21st week of 2012 patent applcation highlights part 41 |
Patent application number | Title | Published |
20120128712 | VACCINE DIRECTED AGAINST PORCINE PLEUROPNEUMONIA AND A METHOD TO OBTAIN SUCH A VACCINE - The present invention pertains to a vaccine directed against porcine pleuropneumonia, comprising lipopolysaccharide, wherein the vaccine comprises a polymyxin to reduce symptoms of an endotoxic shock arising from the lipopolysaccharide. The invention also pertains to a method to obtain such a vaccine and a method for administering the vaccine to a subject animal. | 2012-05-24 |
20120128713 | Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus - Replication-defective vaccine vectors against respiratory syncytial virus (RSV) are disclosed. Corresponding compositions and methods employing the vaccine vectors are also disclosed. | 2012-05-24 |
20120128714 | Alphavirus Replicon Particles Expressing TRP2 - The immune response to melanoma cells and tumors can be induced or significantly increased by administering to a subject a pharmaceutical composition comprising alphavirus particles, especially Venezuelan equine encephalitis virus replicon particles, which express the melanoma antigen dopachrome tautomerase (DCT, TRP2) in cells of the subject, with the result of tumor regression and/or inhibition of metastasis of a melanoma subject, or a decreased risk of the occurrence or recurrence of melanoma and/or decreased severity of melanoma in a subject not suffering from melanoma at the time of administration. The pharmaceutical composition described herein can be used in conjunction with other therapeutic agents, it can be administered on more than one occasion and it can be combined with administrations of other compositions such as protein or other immunogenic compositions, and/or adjuvants, with beneficial effects to the human or animal subject to which it has been administered. | 2012-05-24 |
20120128715 | METHOD FOR STIMULATING THE IMMUNE RESPONSE OF NEWBORNS - The present invention is based on the surprising discovery that agonists of TLR8 are uniquely efficacious in enhancing (e.g. inducing) the immune response of newborns. Thus, agonists of TLR8 serve as both vaccine adjuvants and as adjunctive therapies for acute infection in newborns, preferably the agonist is a TLR8-selective agonist. The immune response induced, or enhanced, in the neonatal host can be, for example, a cytokine immune response and/or a humoral immune response (e.g., antigen-specific). | 2012-05-24 |
20120128716 | Vaccine Compositions - Vaccine compositions, useful for eliciting an immune response in subjects which is protective against influenza type A virus, comprise influenza type A virus antigen and a bacterial sialidase. An intranasal vaccine against highly pathogenic subtype H5N1 virus, for use in the treatment of poultry, preferably comprises inactivated H5N1 antigen, sialidase from | 2012-05-24 |
20120128717 | INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE - The present invention is directed to compositions and methods for enhancing the immune response of a human in need of protection against influenza virus (IV) infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof, or a protein encoded thereby. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount. | 2012-05-24 |
20120128718 | ATTENUATED FNR DEFICIENT ENTEROBACTERIA - The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject by administration of an immunogenically effective amount of an attenuated enterobacterium or pharmaceutical formulation of the invention. | 2012-05-24 |
20120128719 | STREPTOCOCCUS VACCINE COMPOSITIONS AND METHODS OF USING THE SAME - The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against a bacterial species of the genus | 2012-05-24 |
20120128720 | MYCOBACTERIUM MUTANTS FOR VACCINES WITH IMPROVED PROTECTIVE EFFICACY - Tuberculosis (TB) is a major health problem and currently, the only licensed TB vaccine is | 2012-05-24 |
20120128721 | SCHISTOSOMA VACCINE - The method for large scale production of a full length Schistosomal paramyosin coiled coil dimer composition is carried out by providing a composition comprising recombinant paramyosin, contacting the composition with a strand separation agent to remove paramyosin fragments and other contaminants. The purified paramyosin is used in vaccines for humans and bovine animals to induce immunity against schistosomal infection. | 2012-05-24 |
20120128722 | Novel Monensin Derivatives for the Treatment and Prevention of Protozoal Infections - This invention relates to novel polyether ionophores, formulations comprising same, and to methods of making and using these compounds and formulations for the treatment and/or prevention of parasitic infection in animals and humans. These compounds exhibit improved safety profiles and/or efficacies as compared to parent compounds. | 2012-05-24 |
20120128723 | CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS - The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof. | 2012-05-24 |
20120128724 | SYSTEMS AND METHODS FOR TREATING HUMAN INFLAMMATORY AND PROLIFERATIVE DISEASES AND WOUNDS, WITH FATTY ACID METABOLISM INHIBITORS AND/OR GLYCOLYTIC INHIBITORS - Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers. | 2012-05-24 |
20120128725 | DETECTION/MEASUREMENT OF MALARIA INFECTION DISEASE UTILIZING NATURAL IMMUNITY BY HEMOZOIN INDUCTION, SCREENING OF PREVENTATIVE OR THERAPEUTIC MEDICINE FOR MALARIA INFECTION DISEASE, AND REGULATION OF NATURAL IMMUNITY INDUCTION - The instant invention is to provide a method for detecting and measuring malaria infection utilizing the induction by hemozoin (HZ); a method for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection using the method for detecting and measuring; and a means for regulating the induction of innate immunity using the HZ, synthetic HZ, or derivatives thereof as an adjuvant or immunostimulant. Malaria infection is detected and measured of by detecting and measuring HZ-induced, TLR9-mediated, and MyD88-dependent innate immune activity. The detection and measurement of malaria infection can be used to diagnose malaria infection. The method for detecting and measuring is also used for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection. Further, HZ, synthetic HZ, or derivatives thereof are used as an adjuvant or immunostimulant to regulate HZ-induced innate immune induction. | 2012-05-24 |
20120128726 | INFANT FEEDING FORMULAS COMPRISING PROBIOTIC MICRO-ORGANISMS - The present invention relates to the field of infant nutrition. In particular, the present invention relates to infant feeding formulas comprising probiotic micro-organisms. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic micro-organisms, for example. | 2012-05-24 |
20120128727 | BACTERIAL EXPRESSION OF AN ARTIFICIAL GENE FOR THE PRODUCTION OF CRM197 AND ITS DERIVATIVES - The present invention relates to polynucleotide sequences comprising the SEQ ID N° 1 encoding CRM197 and optimised for its expression in | 2012-05-24 |
20120128728 | Compositions Comprising Amphotericin B - The present invention comprises compositions and formulations comprising amphotericin B comprising less than 10% degradants, compositions and formulations comprising amphotericin B with one or more excipients, methods of making amphotericin B compositions and formulations, as well as systems for using amphotericin B compositions and formulations. Also provided are pharmaceutical compositions comprising the formulation, methods of administering the pharmaceutical compositions and methods of treating patients with the pharmaceutical compositions. | 2012-05-24 |
20120128729 | Gallium Formulation For The Treatment And Prevention of Infectious Diseases - A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as | 2012-05-24 |
20120128730 | COMPOSITIONS AND METHODS FOR ONCE-DAILY TREATMENT OF OBSESSIVE COMPULSIVE DISORDER WITH ONDANSETRON - Compositions for once-daily administration of ondansetron are described. Compositions include a core, a semi-permeable membrane disposed generally around the core, an orifice in the semi-permeable membrane in fluid communication with the core, and a coating having a first therapeutically effective dose of ondansetron or a pharmaceutically acceptable salt disposed generally around the semi-permeable membrane. The core includes first, second, and third layers. The first layer is in fluid communication with the orifice. The second layer includes a second therapeutically effective dose of ondansetron or a pharmaceutically acceptable salt and is located adjacent to the first layer. The third layer is located adjacent the second layer. Methods for treating obsessive compulsive disorder by administering these compositions are also described. | 2012-05-24 |
20120128731 | BIOCOMPATIBLE CARRIER AND METHOD FOR FABRICATING THE SAME - The invention provides a biocompatible carrier and method for fabricating the same. The biocompatible carrier includes: a gel, and a plurality of metal nanoparticles, an organic compound or combinations thereof embedded in the gel, wherein the metal nanoparticles, the organic compound or combinations thereof are uniformly distributed in the gel. | 2012-05-24 |
20120128732 | COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that inhibits a pro survival and/or inflammatory signal. | 2012-05-24 |
20120128733 | PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE DRUGS, CONTRACEPTIVE KITS COMPRISING ACTIVE DRUGS, AND METHODS OF ADMINISTERING THE SAME - The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptives (“POC”), such as Drospirenone. | 2012-05-24 |
20120128734 | Oral Delivery Product - An oral delivery product comprising a semi-permeable pouch designed for delivery of an active agent in the oral cavity of a subject. The pouch encloses multiple particles, and the particles are alginate matrices that comprise an active agent, e.g. nicotine. The alginate is e.g. sodium alginate, such as Protanal LFR 5/60 or Protanal LF 10/60. | 2012-05-24 |
20120128735 | METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE - A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. | 2012-05-24 |
20120128736 | OIL-IN-WATER EMULSION OF MOMETASONE - Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, butylene glycol and water and the weight ratio between the butylene glycol and water contained in the oil-in-water emulsion is from 1:1 to about 1:3. | 2012-05-24 |
20120128737 | COMPOSITIONS FOR TREATING DEGENERATIVE JOINT DISEASES - In order to provide a composition for the treatment of degenerative joint diseases with an improved efficacy, it is proposed that the composition comprises collagen hydrolysate and rosehip powder and/or extract, wherein the weight ratio of collagen hydrolysate to rosehip powder and/or extract, in each case in relation to dry mass, lies in the range of approximately 2:1 to approximately 100:1. | 2012-05-24 |
20120128738 | Theobromine for the Treatment of Cough - The present invention is theobromine as an active agent to be delivered via the inhaled route, for the treatment of cough. | 2012-05-24 |
20120128739 | THREE-DIMENSIONAL NANOSTRUCTURED HYBRID SCAFFOLD AND MANUFACTURE THEREOF - A method of making a three-dimensional biocompatible scaffold capable of supporting cell activities such as growth and differentiation, the method includes providing a supporting grid that forms an open network and provides mechanical support of a second biocompatible material. The second biocompatible material has interconnected cavities that allow nutrients, metabolites and soluble factors to diffuse throughout the scaffold. The scaffold design can be understood as a hierarchically organised structure. At the micron to submicron length scale a top/down manufacturing approach is used to make a structure that will constitute the frame into which a bottom/up processing approach is applied to form an open porous scaffold with specific nano sized features. The advantage of this hierarchically organised design is that benefits can be drawn independently from both the micron and the nano sized structures, promoting specific cell activities and providing sufficient mechanical compliance. | 2012-05-24 |
20120128740 | NANOSTRUCTURED SILDENAFIL BASE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND CO-CRYSTALS, COMPOSITIONS OF THEM, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured (nanoparticulated) Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them according to the invention have an average particle size of less than about 500 nm. Sildenafil citrate is inhibiting cGMP specific phosphodiesterase type 5 (PDEV), an enzyme that regulates blood flow in the penis. The compositions of the invention are useful in the treatment of male or female sexual dysfunction and pulmonary arterial hypertension (PAH). | 2012-05-24 |
20120128741 | MODIFIED HYALURONIC ACID POLYMER COMPOSITIONS AND RELATED METHODS - The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses. | 2012-05-24 |
20120128742 | SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF AN INHIBITOR OF APOPTOSIS PROTEIN - The present disclosure relates to crystalline form of (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same. | 2012-05-24 |
20120128743 | POLYMER PARTICLES - The present invention relates to a method of forming polymer on the surface of polymer particles, the method comprising:
| 2012-05-24 |
20120128744 | MIXTURE CONTAINING MENTHOL - The present invention relates to d,l-menthol and optionally additionally l-menthol-containing mixtures, which are liquid at normal pressure and a temperature of 20° C. or higher. The present invention further relates to products that comprise such a mixture or that are preparable by mixing or contacting such a mixture with further ingredients, and novel processes for preparing menthol-containing products. | 2012-05-24 |
20120128745 | BENZYLIDENE MALONATES - Disclosed is the use of benzylidene malonates of formula (1) | 2012-05-24 |
20120128746 | Cosmetic Nanocomposites based on in-situ crosslinked POSS materials - A cosmetic composition for caring for and/or making up the skin, lips and/or body in the form of a film, which is non-transferable, long-lasting with a comfortable feeling of use to consumers over long periods of wear time. The composition contains graftable POSS which forms a film when it cures in situ. The invention also relates to using such film for preparing a cosmetic composition and a makeup process and makeup kit comprising the product. | 2012-05-24 |
20120128747 | CORE-SHELL MATERIAL, METHOD FOR PREPARING SAME, AND USE THEREOF FOR THE THERMOSTIMULATED GENERATION OF SUBSTANCES OF INTEREST - The present invention relates to a material in the form of solid particles consisting of a continuous shell including at least one silicon oxide, said shell confining at least one oil phase, said material being characterized in that said oil phase is solid at the storage temperature of said material and predominately contains a crystallizable oil that has a melting temperature (T | 2012-05-24 |
20120128748 | Organic-Inorganic Composite Particles, Process for Producing the Same, Dispersion Containing the Particles, and Cosmetic Containing the Particles - Organic-inorganic composite particles includes inorganic oxide particles each of which has a cationic charge on the particle surface and polymer gel molecules which are derived from a natural substance, have an anionic functional group and one or more hydroxyl groups in a molecule and have both a shrinking and a swelling property, the polymer gel molecules are electrostatically bonded to surfaces of the inorganic oxide particles; a process for producing the particles; a dispersion containing the particles; and a cosmetic containing the particles. These organic-inorganic composite particles have good dispersibility not only in aqueous solvents such as water but also in non-aqueous solvents and further have characteristics that aggregation of the particles scarcely occurs. | 2012-05-24 |
20120128749 | COMPOSITION AND PROCESS FOR PRODUCTION THEREOF - Disclosed are: a composition which enables the more effective development of the efficacy of a water-soluble drug in a solution containing the drug; and a dispersion in which a hydrophobic drug can be dispersed stably without requiring the use of any surfactant. Specifically disclosed are: a composition comprising ultra-fine bubbles having a mode particle size of 500 nm or less, a drug and water; and a process for producing a composition comprising ultra-fine bubbles having a mode particle size of 500 nm or less, a drug and water, which utilizes an ultra-fine bubble generation apparatus. | 2012-05-24 |
20120128750 | PROCESS FOR PREPARING AN AQUEOUS SUSPENSION OF AN ORGANIC PESTICIDE COMPOUND - The present invention relates to a process for preparing an aqueous suspension of an organic pesticide compound, which has a solubility in water of not more than 2 g/l at 20° C. and a melting point of not more than 110° C. and which is capable of forming at least one crystalline modification, wherein the organic pesticide compound is present in the form of essentially crystalline particles, which process comprises: a) providing an aqueous emulsion of the organic pesticide compound, wherein the organic pesticide compound is present in the form droplets of an amorphous form of the organic pesticide compound, and b) addition of an aqueous suspension of said organic pesticide compound, wherein the organic pesticide compound is present in the form of essentially crystalline particles, wherein the addition in step b) is performed at a temperature below the melting temperature of the crystalline form of the organic pesticide compound. | 2012-05-24 |
20120128751 | PRESERVATION OF LIQUID FOODS - Anti-spoilage inserts and methods are provided for inhibiting the spoilage of liquid foods. | 2012-05-24 |
20120128752 | MULTI-PHASE MICROPARTICLES AND METHOD OF MANUFACTURING MULTI-PHASE MICROPARTICLES - The invention relates to a method of manufacturing multi-phase microparticles. The method comprises dissolving at least three different polymers in a volatile organic solvent to obtain a first solution. The first solution comprises at least two cloud points, wherein the second cloud point is higher than the first cloud point. Viscosity of the first solution and the first and second cloud point are selected such that the at least three different polymers are immiscible with each other in the first solution. The first solution is dispersed into an aqueous continuous phase which comprises a surfactant to obtain an emulsion. The volatile organic solvent is evaporated from the emulsion. The total concentration of the at least three different polymers together in the emulsion before evaporation is below the first cloud point, or is above the first cloud point and below the second cloud point or is above the second cloud point. The invention relates also to a multi-phase microparticle made by the method and a pharmaceutical composition comprising the multi-phase microparticle. | 2012-05-24 |
20120128753 | MEDITOWEL PRE-PACKAGED MEDICATED MUSCLE AND JOINT PAIN RELIEF WIPE - Single use, substrate uniformly impregnated with an anhydrous muscle and joint pain relief solution for the use of aseptically delivering a single dose of a muscle and joint pain relief solution to the area of pain. Solution and substrate is contained encapsulated within a heat sealed foil enclosure that is stable for at least five years. | 2012-05-24 |
20120128754 | TREATMENT OF EYE DISCOMFORT BY TOPICAL ADMINISTRATION OF A COOLING AGENT TO THE EXTERNAL SURFACE OF THE EYELID - The present invention pertains generally to the field of ocular treatment, and more specifically to the use of a liquid cooling agent composition comprising a cooling agent for the treatment of (e.g., the alleviation of symptoms of; the amelioration of) eye discomfort. The preferred cooling agent is (1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarboxylic acid 2,3-dihydroxy-propyl ester (referred to herein as CPS-030). The liquid cooling agent composition is topically administered to at least a portion of the external surface of the eyelid (preferably the closed eyelid) of the eye to be treated. Preferably, the liquid cooling agent composition is carried on or in a wipe, pad, or towelette, for example, an eye wipe. | 2012-05-24 |
20120128755 | Personal Care Composition Containing Yeast Extract And Hexapeptide - A personal care composition comprising (a) a yeast extract, (b) Hexapeptide-11 (Phe-Val-Ala-Pro-Phe-Pro) (SEQ ID NO:1), and (c) a determatologically-acceptable carrier, wherein the total amount of components (a) and (b) is from about 2 wt % to about 6 wt %, preferably from 4-6% based on the total weight of the personal care composition. Also disclosed is a method for regulating skin conditions by using this composition. | 2012-05-24 |
20120128756 | Skin Permeating And Cell Entering (SPACE) Peptides and Methods of Use Thereof - The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells. | 2012-05-24 |
20120128757 | Method of Manufacture of Liposome Composition - The present invention provides a method of manufacture of a liposome composition including a step in which: a liposome dispersion liquid containing a liposome, and further containing cyclodextrin in the liposome internal phase is provided and a step in which an active compound is introduced into said liposome internal phase, and the liposome composition. | 2012-05-24 |
20120128758 | FORMULATION FOR INDUCING BROADLY REACTIVE NEUTRALIZING ANTI-HIV ANTIBODIES - The present invention relates in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies, and, in particular, to a formulation comprising Toll Like Receptor (TLR) agonists with HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to methods of inducing neutralizing anti-HIV-1 antibodies using such formulations. | 2012-05-24 |
20120128759 | METHOD TO INHIBIT AIRWAY HYPERRESPONSIVENESS USING AEROSOLIZED T CELL RECEPTOR ANTIBODIES - Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system. | 2012-05-24 |
20120128760 | LIPID COMPOSITIONS - Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is (F). Also disclosed are methods of producing the cationic lipid of formula (I). | 2012-05-24 |
20120128761 | Lipophilic Polynucleotide Conjugates - Disclosed are lipophilic polynucleotide conjugates including polynucleotide-cholesterol conjugates and methods of delivering therapeutic polynucleotides to a mammalian cell or patient in need of treatment using said conjugates. The disclosure further provides methods of synthesizing the lipophilic polynucleotide conjugates. The conjugates are designed to mimic or target cellular miRNAs. The lipophilic moiety, such as cholesterol or cholesterol derivative, is spaced from the polynucleotide by a substantially linear hydrocarbon group. Due to an absence of significantly polar groups and/or exchangeable protons in the vicinity of the lipophilic moiety, the interaction between the lipophilic moiety and cell membranes is enhanced to provide for efficient entry into cells. | 2012-05-24 |
20120128762 | Sphingomyelin Liposomes for the Treatment of Hyperactive Bladder Disorders - The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysfunction. | 2012-05-24 |
20120128763 | LUBRICANT FOR THE OCULAR SURFACE - A formulation has been developed for treatment of the symptoms of dry eye which incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear and eyedrop as well as stabilize the eyedrop. The improved performance of the jojoba wax supplemented tear relieves irritation and discomfort as well as sharpens the blurred vision. | 2012-05-24 |
20120128764 | CONTROLLED-RELEASE COMPOSITIONS COMPRISING A PROTON PUMP INHIBITOR - The present invention relates to pharmaceutical compositions, and methods of preparing such compositions, comprising one or more populations of controlled-release particles comprising one or more proton pump inhibitors. The present invention also relates to pharmaceutical dosage forms, including orally disintegrating tablets, tablets, capsules, and methods for their preparation. | 2012-05-24 |
20120128765 | METHOD AND DEVICE FOR PRODUCING SOFT CAPSULES - The claimed subject matter relates to a rotary die device for producing soft capsules, comprising a capsule forming unit for forming a soft-capsule shell and a dosing unit for feeding a filling material into the capsule forming unit, characterized in that the dosing unit comprises a conveying apparatus of viscous melts and a portioner, wherein the portioner is connected at an end thereof to the conveying apparatus of viscous melts and is arranged in a filling wedge with a section in such a way that filling material from the portioner reaches the location of the capsule filling directly or by means of one or more channels having a length of at most 30 mm. Using said device, high-viscosity filling materials can be filled and thus novel soft capsules can be made accessible. | 2012-05-24 |
20120128766 | Self-Breaking Tablets - Self-breaking core tablets and functionally coated tablets and capsule formulations are provided. Methods for production of these tablet and capsule formulations and their administration are also provided. | 2012-05-24 |
20120128767 | THERAPEUTIC CALCIUM PHOSPHATE PARTICLES AND METHODS OF MAKING AND USING SAME - The present invention provides novel calcium phosphate nanoparticles suitable for efficient encapsulation of biologically active molecules. The invention further provides pharmaceutical compositions comprising these nanoparticles, as well as methods of making such nanoparticles and using them as carriers for therapeutic delivery of biologically active macromolecules. | 2012-05-24 |
20120128768 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY - The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. | 2012-05-24 |
20120128769 | Solubilized CoQ-10 - The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules. | 2012-05-24 |
20120128770 | TREATMENT OF INSULIN RESISTANCE AND OBESITY BY STIMULATING GLP-1 RELEASE - The present invention relates to 1 or 2 C16-C18 acyl glycerol based compounds which are capable of activating G-protein coupled receptor 119 and thereby stimulate GLP-1 release. Compounds of the present invention are useful in the prophylaxis and/or treatment of metabolic disorders and complications thereof, such as, type 2 diabetes mellitus (T2DM), obesity, insulin resistance, and cardiovascular disease. | 2012-05-24 |
20120128771 | TIMED, PULSATILE RELEASE SYSTEMS - A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications. | 2012-05-24 |
20120128772 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF MILNACIPRAN - A controlled release pharmaceutical composition comprising Milnacipran or pharmaceutically acceptable salts thereof and hydrophobic release controlling agent. The composition releases 90% of the total amount of Milnacipran or pharmaceutically acceptable salts thereof between 8 to 20 hours when dissolution is carried out in 900 ml 0.1N HCl, USP apparatus Type I (Basket) at 100 rpm for 2 hrs, followed by 900 ml Phosphate buffer pH 6.8 USP apparatus Type I (Basket) at 100 rpm. A process of preparing a controlled release pharmaceutical composition comprises: a) preparing a first layer comprising i) melting hydrophobic release controlling agent and Milnacipran or pharmaceutically acceptable salts thereof in it ii) cooling followed by sieving the melted mass to obtain granules and iii) lubricating the granules; and b) preparing a second layer comprising granules which comprises hydrophobic release controlling agent and optionally Milnacipran or pharmaceutically acceptable salts thereof | 2012-05-24 |
20120128773 | DESFESOTERODINE IN THE FORM OF A TARTARIC ACID SALT - The invention concerns desfesoterodine in the form of a tartaric acid salt, in particular in the polymorphic “R form”, as well as a process for its production. In a second aspect, the invention concerns the desfesoterodine of the invention in a microencapsulated form. | 2012-05-24 |
20120128774 | MAXILLOFACIAL BONE AUGMENTATION USING RHPDGF-BB AND A BIOCOMPATIBLE MATRIX - The present invention provides effective new methods and materials for maxillofacial bone augmentation, particularly alveolar ridge augmentation, that are free of problems associated with prior art methods. In one embodiment, these materials include human recombinant platelet derived growth factor (rhPDGF-BB) and a biocompatible matrix. In another embodiment, these materials include rhPDGF-BB, a deproteinized bone block or calcium phosphate, and a bioresorbable membrane. The use of these materials in the present method is effective in regenerating maxillofacial bones and facilitating achievement of stable osseointegrated implants. The mandible and maxilla are preferred bones for augmentation, and enhancement of the alveolar ridge is a preferred embodiment of the present invention. | 2012-05-24 |
20120128775 | BIOCARRIER AND METHOD OF USING THE SAME - The present invention discloses a biocarrier for delivery of a bioactive substance near/into a target cell, comprising a bioactive substance-loaded core with a first electricity, and one or more block copolymer, each block copolymer comprising a zwitterionic block and an anchoring block with an initial electricity opposite to the first electricity, wherein the anchoring block binds to the core by electrostatic attraction, and the zwitterionic block extends outwardly to increase the biocarrier stability in mammalian blood. Additionally, the present invention also discloses a method of using the biocarrier. | 2012-05-24 |
20120128776 | METHOD FOR THE PREPARATION OF MICROPARTICLES WITH EFFICIENT BIOACTIVE MOLECULE INCORPORATION - The present invention relates to relates to a method for the preparation of drug filled polymer microparticles comprising a gas core and shell, which particles are suitable as part of a therapeutic composition, especially for drug delivery. By using this method, polymeric microparticles are obtained that combine high incorporation efficiency for hydrophilic and/or hydrophobic drugs with a large, preferably hollow, core. | 2012-05-24 |
20120128777 | COMPOSITIONS CONTAINING LIPID MICRO- OR NANOPARTICLES FOR THE ENHANCEMENT OF THE DERMAL ACTION OF SOLID PARTICLES - The invention is related to compositions which can be used as dermal formulations for supporting the skin to restore normal conditions in case of e.g. irritated skin, or to support medical therapy of skin with atopic dermatitis symptoms, atopic dermatitis, psoriasis or related diseases (e.g. accompanied by distorted barrier function of the skin and microbial load). The compositions of the invention can be used for dermo-cosmetic products but also for pharmaceutical/-medical products, depending on the composition and the additional actives incorporated (cosmetic actives or drugs). The invention is based on the synergistic effect of metallic particles, in particular silver particles (such as microsilver, nanosilver) and lipid particles (lipid nanoparticles or lipid microparticles). As alternatives to silver particles, other metallic particles (e.g. zinc, copper) or nanocrystalline actives can be incorporated (e.g. replacing the anti-oxidative silver by anti-oxidative nanocrystals of plant molecules such as hesperitin). This leads to combinations of lipid particles with nanocrystals for dermal use. | 2012-05-24 |
20120128778 | COMPOSITIONS AND METHODS FOR ONCE-DAILY ADMINISTRATION OF A TRILAYER OSMOTIC TABLET - A trilayer osmotic tablet is described. The tablet includes a core, a semi-permeable membrane disposed generally around the core, and an orifice in the semi-permeable membrane in fluid communication with the core. The core includes first, second, and third layers. The first layer is in fluid communication with the orifice. The second layer includes a therapeutically effective dose of a drug and is located adjacent to the first layer. The third layer is located adjacent the second layer. The tablet may include a coating having therapeutically effective doses of at least one additional drug disposed in the coating that generally surrounds the semi-permeable membrane. The at least one additional drug in the coating may be the same or different from the drug in the trilayer core. Methods for treating epilepsy, psychiatric disorders, asthma, and peptic ulcer disease by administering these compositions are also described. | 2012-05-24 |
20120128779 | PROCESS FOR PRODUCING PROTEIN MICROPARTICLES - The present invention relates to a process for producing protein microparticles in dilute organic acid solutions and in the absence of an alcohol such as ethanol. The microparticles are formed by dissolving a cereal prolamin protein in a concentrated organic acid solution with agitation and then diluting the solution with an aqueous solution. Protein microparticles having vacuoles are thus formed. The protein microparticles may be used to form powders, films, coatings, matrices, scaffolds and the like. Complete films can be formed from the protein microparticles of the invention. | 2012-05-24 |
20120128780 | NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS - Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal. | 2012-05-24 |
20120128781 | FUNCTIONALIZATION OF NANOPARTICLES BY GLUCOSAMINE DERIVATIVES - The present invention relates to oligomeric or polymeric saccharide derivatives comprising glucosamine moieties, e.g. derivatives of oligomeric or polymeric glucosamines such as chitosan oligomers or polymers, in which one or more amine groups are substituted by anchoring groups that chemisorb to the surface of a nanoparticle or form an interdigitated bilayer with a surfactant layer surrounding the nanoparticle. The invention also relates to functionalized nanoparticles comprising such derivatives, a method for forming the functionalized particles and to uses thereof as molecular imaging agents, biosensing agents or drug delivery agents, or in the preparation of such agents. | 2012-05-24 |
20120128782 | Multicomponent Degradable Cationic Polymers - Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such as LIPOFECTAMINE | 2012-05-24 |
20120128783 | Compositions and methods for delivery of frozen particle adhesives - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2012-05-24 |
20120128784 | COMPOSITION CONTAINING BEE VENOM AS AN ACTIVE INGREDIENT FOR PREVENTING AND TREATING ACNE - The present invention relates to a composition for preventing and treating acne, comprising a material which has excellent antibacterial activity against | 2012-05-24 |
20120128785 | Biological nasal bridge implant and method of manufacture - A nasal bridge implant is made according to a method that includes the steps of collecting animal material from a bovine or porcine source, the animal material being either a tendon or a ligament, removing cells from the animal material, shaping the animal material to provide a desired shape for the nasal bridge implant, crosslinking the animal material, removing antigens from the animal material, subjecting the animal material to an alkaline treatment, coupling into the animal material active substances which are capable of adhering growth factor and stem cell, and packing the animal material in a container that contains a sterilization solution. | 2012-05-24 |
20120128786 | Delivery System Comprising A Silicon-Containing Material - A composition comprising nanoparticles of a hydrolysable silicon-contain material for use as a delivery system for a bioactive ingredient, wherein surface of the silicon-containing material is associated with a stabilizing agent which modifies the rate of hydrolysis of the silicon-contain material and/or inhibits the rate of orthosilicic acid polymerisation and a method of promoting the controlled release of orthosilicic acid on degradation of a composition comprising nanoparticles of a hydrolysable silicon-contain material, the method involving the treatment of the surface of the silicon-containing material with a stabilizing agent to modify the rate of hydrolysis of the silicon-containing material and/or inhibit the rate of orthosilicic acid polymerisation. | 2012-05-24 |
20120128787 | Homeopathic Composition Comprising Hypericum Perforatum Extract And Essential Oils For The Treatment Of Neuropathic Pain - The present invention provides a method of treating neuropathic pain by administering a topical homeopathic composition to a mammalian subject. The homeopathic formulation contains homeopathic active ingredients comprising | 2012-05-24 |
20120128788 | COLLAGEN PRODUCTION ENHANCER - A collagen production enhancer for increasing the amount of collagen contained in the skin tissues, comprising calcium phosphate fine particles as effective ingredients. | 2012-05-24 |
20120128789 | USE OF XENON FOR TREATING HYPERSENSITIVITY TO PAIN - The invention relates to a gaseous mixture containing oxygen (O2) and a volume proportion of 20 to 70% of xenon (Xe) for use as an inhalable drug for preventing or treating hypersensitivity to pain in humans or animals, in particular hypersensitivity to pain expressed as hyperalgesia or allodynia. | 2012-05-24 |
20120128790 | GRANULAR ANTIMICROBIAL AGENT FOR WATER PROCESSING - [Object] The object of the invention is to provide a granular antimicrobial agent for water processing which has sufficient water permeability and antimicrobial effect, and the effective duration of which can be readily ascertained when used as a water-processing antimicrobial agent in the home. | 2012-05-24 |
20120128791 | Ammoniacal Copper Zinc Arsenate Concentrates and Methods of Preparation - Disclosed herein is a composition concentrate that is suitable for treating wood upon dilution with water in a weight ratio of concentrate to water of between 1:10 and 1:100. The concentrate contains copper ammonium cations, zinc ammonium cations, arsenate and/or hydrogen arsenate anions; carbonate and/or bicarbonate anions, ammonia and water, wherein the total amount of copper and zinc is from 17% to about 22% by weight based on the total volume of the concentrate. Also disclosed is a process for producing ammoniacal copper zinc arsenate concentrate. | 2012-05-24 |
20120128792 | Trace Elements - The inventions discloses a trace element solution, which comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium. | 2012-05-24 |
20120128793 | IMPLANTABLE OR INSERTABLE MEDICAL DEVICE RESISTANT TO MICROBIAL GROWTH AND BIOFILM FORMATION - Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and a microbial adhesion/biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device. Also disclosed are methods of manufacturing such devices under conditions that substantially prevent preferential partitioning of any of said bioactive agents to a surface of the biocompatible matrix polymer and substantially prevent chemical modification of said bioactive agents | 2012-05-24 |
20120128794 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM - Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual. | 2012-05-24 |
20120128795 | COLORLESS, NON-FUMING, HAZARDLESS AND STABLE AQUA-REGIA, ITS PREPARATION METHOD AND USE IN TREATING MEDICAL DISORDERS - A method for production of colorless, non-fuming, hazardless and stable aqua-regia solution is provided. The method includes heating a dry mixture of potassium nitrate, potassium chloride and potassium aluminum sulphate to obtain vapors of aqua-regia and condensing the vapors obtained to form a colorless, non-fuming, hazardless and stable aqua-regia solution. The method produces aqua-regia directly from dry salts without adding any single drop of solvent. Aqua-regia obtained by this method is highly stable and possesses dual property of being an anti-diarrheal as well as a rehydrating compound. | 2012-05-24 |
20120128796 | Extracts and Compounds from Ficus Benghalensis for Increasing Hair Growth and Decreasing Hair Loss - This application discloses natural product extracts and compounds from an aerial root of a | 2012-05-24 |
20120128797 | METHOD FOR TREATMENT OF CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME - The present invention provides methods for treating constipation-predominant irritable bowel syndrome comprising administering to a patient in need thereof, a polymeric proanthocyanidin composition from a | 2012-05-24 |
20120128798 | Method of Treating Neurological Conditions with Extract of Nerium Species or Thevetia Species - A method of treating neurological condition in a subject by administration of an extract, or fraction or sub-fraction thereof, of | 2012-05-24 |
20120128799 | Soft Dried Marshmallow and Method of Preparation - Dried soft aerated confections and methods of their preparation are provided having a water activity of about 0.1 to 0.4 and a glass transition temperature of less than 20° C. The confections comprise sugars, a foaming and a structuring ingredient, preferably each gelatin, and about 5 to 15% softening agent. Preferred softening agents include glycerin, polyglycerols and mixtures thereof. The confections are aerated to densities of about 0.1 to 0.5 g/cc. The soft dried aerated confections are particularly suited for addition to children's Ready-To-Eat cereals in the form of pieces weighing about 0.1 to 2 g each. The dried confection pieces maintain their soft texture over time without causing moisture migration to the cereal. | 2012-05-24 |
20120128800 | DIETARY SUPPLEMENTS CONTAINING EXTRACTS OF ARONIA AND METHOD OF USING SAME TO PROMOTE WEIGHT LOSS - A dietary supplement composition comprising aronia extract containing at least 20% anthocyanins by dry weight. The aronia extract is derived from the aronia melanocarpa plant. The aronia extract comprises approximately 10%-30% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is provided in the composition. The dietary supplement composition is administered orally to promote weight loss. | 2012-05-24 |
20120128801 | COMBINATION HERBAL PRODUCT TO BENEFIT RESPIRATORY TRACT IN PEOPLE EXPOSED TO SMOKE - An herbal composition for providing a beneficial effect to the respiratory tract. The composition includes Thyme Leaf, Wild Cherry Bark, Cocoa Extract, Mullein Leaf Extract, and | 2012-05-24 |
20120128802 | BITTERNESS SUPPRESSANT - The present invention relates to a bitterness suppressant derived from a juice of a stone fruit, and more specifically to a bitterness suppressant characterized by being derived from a juice of a stone fruit wherein a low molecular weight saccharide has been removed. | 2012-05-24 |
20120128803 | PROCESS FOR PREPARING WATER EXTRACT OF CINNAMON - This invention relates to an improved process for preparing water extract of cinnamon in a large scale. The process comprises the steps of: (a) adding an aqueous solvent such as water to at least 5 kg of a cinnamon raw material at a water to material ratio of 1:1 to 100:1, (b) boiling the mixture of (a) for at least 5 minutes, (c) removing the solid debris from the mixture, (d) storing the liquid portion of the mixture at about −5 to 25° C., preferably 0-10° C., until a top layer of oil is formed and partitioned, (e) removing the top layer of oil, and (f) collecting the remaining liquid portion. The present process prepares a cinnamon water extract product with a minimal content of potentially toxic cinnamaldehyde and coumarin, while increasing the contents of the active ingredients of polyphenolic polymers for controlling blood glucose level. | 2012-05-24 |
20120128804 | PROCESS FOR PREPARING WATER EXTRACT OF CINNAMON - This invention relates to an improved process for preparing water extract of cinnamon in a large scale. The process comprises the steps of: (a) adding an aqueous solvent such as water to at least 5 kg of a cinnamon raw material at a water to material ratio of 1:1 to 100:1, (b) boiling the mixture of (a) for at least 5 minutes, (c) removing the solid debris from the mixture, (d) storing the liquid portion of the mixture at about −5 to 25° C., preferably 0-10° C., until a top layer of oil is formed and partitioned, (e) removing the top layer of oil, and (f) collecting the remaining liquid portion. The present process prepares a cinnamon water extract product with a minimal content of potentially toxic cinnamaldehyde and coumarin, while increasing the contents of the active ingredients of polyphenolic polymers for controlling blood glucose level. | 2012-05-24 |
20120128805 | LONG-LASTING GUSTATORY AND/OR OLFACTORY AVERSION VETERINARY COMPOSITIONS FOR BEHAVIOR MODIFICATION - Disclosed herein are gustatory and/or olfactory aversion compositions comprising one or more bitterants and appropriate adhesives or tackifiers, and the like, which provide a long-lasting effect. The compositions are useful for behavior modification, especially in animals, such as pets or livestock. | 2012-05-24 |
20120128806 | WEIGHT REDUCTION SYSTEM AND METHOD - A method of topically applying natural plant product for dissipation of human adipose tissue, comprising: (a) topically applying an inner portion of a natural plant product to an epidermal layer exterior to adipose tissue to be dissipated of a user's body for a period of time, upon which a percentage of the adipose tissue softens and dissolves, thus, reducing the adipose tissue of the user's body; (b) removing the topically applied inner portion of the natural plant product from the epidermal layer for another period of time; (c) repeating steps (a) and (b); and weight reduction apparatus comprising a topical applicator having a receiving container adapted to removably receive a natural plant product and having an opening or a porous wall adapted to facilitate pulp, juices, and/or extracts of the natural plant product to contact a user's epidermal layer exterior to the adipose tissue to be dissipated. | 2012-05-24 |
20120128807 | COMPOSITION FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME - The present invention relates to a composition or a method for treating or preventing irritable bowel syndrome. The present invention uses | 2012-05-24 |
20120128808 | AGENTS FROM FICUS HISPIDA FOR THE AMELIORATION OF METABOLIC SYNDROME AND RELATED DISEASES - The invention discloses herbal ingredient(s) derived from | 2012-05-24 |
20120128809 | INDUCTION HEATING DEVICE AND METHOD FOR MAKING A WORKPIECE USING SUCH A DEVICE - The invention concerns a device for heating a surface by induction, in particular for molding or transforming a part made of thermoplastic or thermosetting composite material. The device comprises a body having at least one portion made of magnetic and heating conducting material wherein is provided a plurality of closed cavities proximate the surface to be heated, each cavity surrounding a field winding. The heat produced by induction on the walls of the cavity is transferred by conduction to the heating surface. The distance between the cavities and the position of said cavities relative to the heating surface are such that the heating is substantially uniform on said surface. | 2012-05-24 |
20120128810 | SYSTEM FOR AUTOMATICALLY PRODUCING WIND TURBINE BLADES - The invention relates to a system for the automatic manufacture of wind turbine blades using die halves ( | 2012-05-24 |
20120128811 | DOUBLE-SIDED IMPRINTING DEVICE - A double-sided imprinting device includes a top-side stamper device supported by a going up and down mechanism, and a bottom-side stamper device and a transferred body detachment device firmly provided on a moving table placed on a guide rail, in which the moving table can be moved back and forth on the guide rail by a movement driving mechanism, with a position of the top-side stamper device as a center, the bottom-side stamper device and the transferred body detachment device can move alternately to a position opposing the top-side stamper device. A bottom-side stamper provided at the bottom-side stamper device has a rectangular shape and a top-side stamper provided at the top-side stamper device has a rectangular shape so that the rectangular-shaped bottom-side stamper and the rectangular-shaped top-side stamper are provided so as to oppose in a cross shape. | 2012-05-24 |